Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Jefferies Group raised their FY2019 EPS estimates for Atara Biotherapeutics in a report issued on Wednesday. Jefferies Group analyst M. Raycroft now expects that the biotechnology company will post earnings per share of ($5.23) for the year, up from their prior estimate of ($5.37). Jefferies Group has a “Buy” rating and a $30.00 price target on the stock. Jefferies Group also issued estimates for Atara Biotherapeutics’ FY2020 earnings at ($4.69) EPS and FY2021 earnings at ($3.49) EPS.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05).
Shares of Atara Biotherapeutics (ATRA) opened at $14.80 on Friday. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.
Several hedge funds have recently bought and sold shares of ATRA. Eagle Asset Management Inc. increased its position in shares of Atara Biotherapeutics by 17.8% in the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after purchasing an additional 225,367 shares during the last quarter. Neuberger Berman Group LLC grew its position in Atara Biotherapeutics by 15.2% during the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after acquiring an additional 147,061 shares during the last quarter. Morgan Stanley grew its position in Atara Biotherapeutics by 147.6% during the first quarter. Morgan Stanley now owns 175,058 shares of the biotechnology company’s stock valued at $3,597,000 after acquiring an additional 104,369 shares during the last quarter. Artal Group S.A. grew its position in Atara Biotherapeutics by 20.0% during the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $9,930,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Atara Biotherapeutics by 10.9% during the first quarter. Vanguard Group Inc. now owns 831,925 shares of the biotechnology company’s stock valued at $17,095,000 after acquiring an additional 81,634 shares during the last quarter. Institutional investors own 85.61% of the company’s stock.
In related news, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $15.30, for a total value of $91,800.00. Following the transaction, the executive vice president now directly owns 349,305 shares in the company, valued at $5,344,366.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Isaac E. Ciechanover sold 2,200 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $15.25, for a total transaction of $33,550.00. Following the completion of the transaction, the chief executive officer now owns 737,767 shares in the company, valued at $11,250,946.75. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 45,988 shares of company stock worth $670,920. 16.20% of the stock is owned by company insiders.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.